Multicenter Trial for Adults With Partial Seizures
Completed
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2
To compare seizure frequency in patients with refactory partial seizures (with or without
generalization) who are taking Talampanel versus placebo as an add-on therapy to other
licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in
this group of patients.
Multicenter Trial for Adults With Partial Seizures
Completed
Teva Pharmaceutical Industries
Phase 2
To compare seizure frequency in patients with refactory partial seizures (with or without
generalization) who are taking Talampanel versus placebo as an add-on therapy to other
licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in
this group of patients.
Effects of Talampanel on Patients With Advanced Parkinson's Disease
Completed
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/Phase 2
The purpose of this research study is to test the safety and effectiveness of the study drug,
Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a
result of treatment to Parkinson's disease.
It is not clear why people with Parkinson's disease develop involuntary movements
(dyskinesias) but studies show that blocking receptors in the brain for a chemical called
glutamate decreases these movements. Talampanel is a drug which blocks these receptors.
Effects of Talampanel on Patients With Advanced Parkinson's Disease
Completed
Teva Pharmaceutical Industries
Phase 1/Phase 2
The purpose of this research study is to test the safety and effectiveness of the study drug,
Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a
result of treatment to Parkinson's disease.
It is not clear why people with Parkinson's disease develop involuntary movements
(dyskinesias) but studies show that blocking receptors in the brain for a chemical called
glutamate decreases these movements. Talampanel is a drug which blocks these receptors.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
